Concurrent versus sequential administration of CMF chemotherapy and radiotherapy after breast-conserving surgery in early breast cancer

Tumori

Volumn 97, Issue 3, 2011, Pages 280-285

  Kim, Kyubo ^a   Chie, Eui Kyu ^a   Han, Wonshik ^a   Noh, Dong Young ^a   Oh, Do Youn ^a   Im, Seock Ah ^a   Kim, Tae You ^a   Bang, Yung Jue ^a   Ha, Sung W ^a  

^a Seoul National University   (South Korea)

Author keywords

Breast conserving surgery; Chemotherapy; Radiotherapy; Sequence

Indexed keywords

CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL EFFECTIVENESS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DISTANT METASTASIS; DOSE RESPONSE; DRUG DOSE SEQUENCE; EARLY CANCER; ERYTHEMA; FEMALE; FOLLOW UP; HUMAN; LUNG TOXICITY; LYMPH NODE METASTASIS; LYMPHEDEMA; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PATIENT COMPLIANCE; PATIENT SAFETY; RADIATION PNEUMONIA; RIB FRACTURE; SKIN EXFOLIATION; SKIN FIBROSIS; SURVIVAL TIME; TUMOR VOLUME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DOSE FRACTIONATION; DRUG ADMINISTRATION SCHEDULE; ESTHETICS; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MASTECTOMY, SEGMENTAL; METHOTREXATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 79960870878     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.1700/912.10022     Document Type: Article

References (31)

1. National Institutes of Health Consensus Development Panel: Consensus statement: Treatment of early-stage breast cancer. J Natl Cancer Inst Monogr, 11: 1-5, 1992.
2. Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, Jeong JH, Wolmark N: Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med, 347: 1233-1241, 2002. (Pubitemid 35176242)
3. Fyles AW, McCready DR, Manchul LA, Trudeau ME, Merante P, Pintilie M, Weir LM, Olivotto IA: Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. N Engl J Med, 351: 963-970, 2004.
4. Early Breast Cancer Trialists' Collaborative Group: Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet, 352: 930-942, 1998.
5. Buchholz TA, Austin-Seymour MM, Moe RE, Ellis GK, Livingston RB, Pelton JG, Griffin TW: Effect of delay in radiation in the combined treatment of breast cancer. Int J Radiat Oncol Biol Phys, 26: 23-35, 1993. (Pubitemid 23137884)
6. Hartsell WF, Recine DC, Griem KL, Murthy AK: Delaying the initiation of intact breast irradiation for patients with lymph node positive breast cancer increases the risk of local recurrence. Cancer, 76: 2497-2503, 1995.
7. Recht A, Come SE, Gelman RS, Goldstein M, Tishler S, Gore SM, Abner AL, Vicini FA, Silver B, Connolly JL: Integration of conservative surgery, radiotherapy and chemotherapy for the treatment of early-stage, node-positive breast cancer: sequencing, timing, and outcome. J Clin Oncol, 9: 1662-1667, 1991.
8. Bellon JR, Come SE, Gelman RS, Henderson IC, Shulman LN, Silver BJ, Harris JR, Recht A: Sequencing of chemotherapy and radiation therapy in early-stage breast cancer: updated results of a prospective randomized trial. J Clin Oncol, 23: 1934-1940, 2005. (Pubitemid 46211372)
9. Isaac N, Panzarella T, Lau A, Mayers C, Kirkbride P, Tannock IF, Vallis KA: Concurrent cyclophosphamide,methotrexate, and 5-fluorouracil chemotherapy and radiotherapy for breast carcinoma: a well tolerated adjuvant regimen. Cancer, 95: 696-703, 2002. (Pubitemid 34839659)
10. Faul C, Brufsky A, Gerszten K, Flickinger J, Kunschner A, Jacob H, Vogel V: Concurrent sequencing of full-dose CMF chemotherapy and radiation therapy in early breast cancer has no effect on treatment delivery. Eur J Cancer, 39: 763-768, 2003. (Pubitemid 36315992)
11. th edn, Springer-Verlag, New York, 2002.
12. Cox JD, Stetz J, Pajak TF: Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys, 31: 1341-1346, 1995.
13. Danoff BF, Goodman RL, Glick JH, Heller DG, Pajak TF: The effect of adjuvant chemotherapy on cosmesis and complications in patients with breast cancer treated by definitive irradiation. Int J Radiat Oncol Biol Phys, 9: 1625-1630, 1983. (Pubitemid 14246661)
14. Kaplan EL, Meier PI: A nonparametric estimation from incomplete observations. J Am Statics Assoc, 53: 457-481, 1958.
15. Huang J, Barbera L, Brouwers M, Browman G, Mackillop WJ: Dose delay in starting treatment affect the outcomes of radiotherapy? A systematic review. J Clin Oncol, 21: 555-563, 2003. (Pubitemid 46606487)
16. Valagussa P, Zambetti M, Biasi S, Moliterni A, Zucali R, Bonadonna G: Cardiac effects following adjuvant chemotherapy and breast irradiation in operable breast cancer. Ann Oncol, 5: 209-216, 1994. (Pubitemid 24097514)
17. Bellon JR, Lindsley KL, Ellis GK, Gralow JR, Livingston RB, Seymour MM: Concurrent radiation therapy and paclitaxel or docetaxel chemotherapy in high-risk breast cancer. Int J Radiat Oncol Biol Phys, 48: 393-397, 2000.
18. Hanna YM, Baglan KL, Stromberg JS, Vicini FA, Decker DA: Acute and subacute toxicity associated with concurrent adjuvant radiation therapy and paclitaxel in primary breast cancer therapy. Breast J, 8: 149-153, 2002. (Pubitemid 34627772)
19. Burstein HJ, Bellon JR, Galper S, Lu HM, Kuter I, Taghian AG, Wong J, Gelman R, Bunnell CA, Parker LM, Garber JE, Winer EP, Harris JR, Powell SN: Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for stage II or III breast cancer. Int J Radiat Oncol Biol Phys, 64: 496-504, 2006. (Pubitemid 43083438)
20. Giordano SH, Kuo YF, Freeman JL, Buchholz TA, Hortobagyi GN, Goodwin JS. Risk of cardiac death after adjuvant radiotherapy for breast cancer. J Natl Cancer Inst, 97: 419-424, 2005. (Pubitemid 40528604)
21. Toledano A, Garaud P, Serin D, Fourquet A, Bosset JF, Breteau N, Body G, Azria D, Le Floch O, Calais G: Concurrent administration of adjuvant chemotherapy and radiotherapy after breast-conserving surgery enhances late toxicities: long-term results of the ARCOSEIN multicenter randomized study. Int J Radiat Oncol Biol Phys, 65: 324-332, 2006.
22. Toledano AH, Bollet MA, Fourquet A, Azria D, Gliogorov J, Garaud P, Serin D, Bosset JF, Miny-Buffet J, Favre A, LeFoch O, Calais G: Does concurrent radiochemotherapy affect cosmetic results in the adjuvant setting after breast-conserving surgery? Results of the ARCOSEIN multicenter, phase III study: patients' and doctors' view. Int J Radiat Oncol Biol Phys, 68: 66-72, 2007. (Pubitemid 46589836)
23. Arcangeli G, Pinnarò P, Rambone R, Giannarelli D, Benassi M: A phase III randomized study on the sequencing of radiotherapy and chemotherapy in the conservative management of early-stage breast cancer. Int J Radiat Oncol Biol Phys, 64: 161-167, 2006. (Pubitemid 43000339)
24. Roue¨ssé J, de la Lande B, Bertheault-Cvitkovic F, Serin D, Graïc Y, Combe M, Leduc B, Lucas V, Demange L, Nguyen TD, Castèra D, Krzisch C, Villet R, Mouret-Fourme E, Garbay JR, Noguès C: A phase III randomized trial comparing adjuvant concomitant chemoradiotherapy versus standard adjuvant chemotherapy followed by radiotherapy in operable node-positive breast cancer: Final results. Int J Radiat Oncol Biol Phys, 64: 1072-1080, 2006.
25. Toledano A, Azria D, Garaud P, Fourquet A, Serin D, Bosset JF, Miny-Buffet J, Favre A, Le Floch O, Calais G: Phase III trial of concurrent or sequential adjuvant chemoradiotherapy after conservative surgery for early-stage breast cancer: final results of the ARCOSEIN trial. J Clin Oncol, 25: 405-410, 2007. (Pubitemid 350002989)
26. Haffty BG, Kim JH, Yang Q, Higgins SA: Concurrent chemoradiation in the conservative management of breast cancer. Int J Radiat Oncol Biol Phys, 66: 1306-1312, 2006.
27. Fisher B, Anderson S, Tan-Chiu E, Wolmark N, Wickerham DL, Fisher ER, Dimitrov NV, Atkins JN, Abramson N, Merajver S, Romond EH, Kardinal CG, Shibata HR, Margolese RG, Farrar WB: Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol, 19: 931-942, 2001. (Pubitemid 32176267)
28. Fisher B, Brown AM, Dimitrov NV, Poisson R, Redmond C, Margolese RG, Bowman D, Wolmark N, Wickerham DL, Kardinal CG: Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol, 8: 1483-1496, 1990. (Pubitemid 20301179)
29. NCCN Practice guidelines in oncology V.1.2010: Breast cancer. Available at http://www.nccn.org/professionals/physician-gls/PDF/breast.pdf (accessed December 3, 2009).
30. Nixon AJ, Schnitt SJ, Gelman R, Gage I, Bornstein B, Hetelekidis S, Recht A, Silver B, Harris JR, Connolly JL: Relationship of tumor grade to other pathologic features and to treatment outcome of patients with early stage breast carcinoma treated with breast-conserving therapy. Cancer, 78: 1426-1431, 1996. (Pubitemid 26317862)
31. Vrieling C, Collette L, Fourquet A, Hoogenraad WJ, Horiot JC, Jager JJ, Bing Oei S, Peterse HL, Pierart M, Poortmans PM, Struikmans H, Van den Bogaert W, Bartelink H: Can patient-,treatment-, and pathology-related characteristics explain the high local recurrence rate following breast-conserving therapy in young patients? Eur J Cancer, 39: 932-944, 2003. (Pubitemid 36428625)